These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35901521)

  • 1. Could small molecules be used in combination with biologics for inflammatory bowel disease?
    D'Amico F; Danese S; Fiorino G
    Expert Rev Clin Immunol; 2022 Oct; 18(10):991-993. PubMed ID: 35901521
    [No Abstract]   [Full Text] [Related]  

  • 2. Surgery for Inflammatory Bowel Disease in the Era of Biologics.
    Lightner AL
    J Gastrointest Surg; 2020 Jun; 24(6):1430-1435. PubMed ID: 32253646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics in Pediatric Inflammatory Bowel Disease.
    Kleinhenz J; Wagner E
    Pediatr Ann; 2022 Feb; 51(2):e77-e81. PubMed ID: 35156888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease.
    Vuijk SA; de Ridder L
    Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1619-1620. PubMed ID: 36352749
    [No Abstract]   [Full Text] [Related]  

  • 5. Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights.
    Chen W; Chen H; Fu S; Lin X; Zheng Z; Zhang J
    Bioprocess Biosyst Eng; 2021 May; 44(5):929-939. PubMed ID: 32458051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic drugs for inflammatory bowel disease.
    Yanai S; Matsumoto T
    Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective.
    Allen PB; Bonovas S; Danese S; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2020 Feb; 20(2):151-161. PubMed ID: 31815548
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
    Wu JF
    Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Therapy for Inflammatory Bowel Disease.
    Grevenitis P; Thomas A; Lodhia N
    Surg Clin North Am; 2015 Dec; 95(6):1159-82, vi. PubMed ID: 26596920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates in therapeutic drug monitoring in inflammatory bowel disease.
    Lodhia N; Rao S
    World J Gastroenterol; 2022 Jun; 28(21):2282-2290. PubMed ID: 35800180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
    Danese S; Gomollon F;
    J Crohns Colitis; 2013 Aug; 7(7):586-9. PubMed ID: 23623738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
    Macaluso FS; Rodríguez-Lago I
    Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Considerations in Inflammatory Bowel Disease.
    McKenna NP; Lightner AL
    Surg Clin North Am; 2019 Dec; 99(6):1083-1094. PubMed ID: 31676049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
    Khoudari G; Mansoor E; Click B; Alkhayyat M; Saleh MA; Sinh P; Katz J; Cooper GS; Regueiro M
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e974-e983. PubMed ID: 33065311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
    Chang S; Hudesman D
    Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.